JP2019509063A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019509063A5 JP2019509063A5 JP2018568183A JP2018568183A JP2019509063A5 JP 2019509063 A5 JP2019509063 A5 JP 2019509063A5 JP 2018568183 A JP2018568183 A JP 2018568183A JP 2018568183 A JP2018568183 A JP 2018568183A JP 2019509063 A5 JP2019509063 A5 JP 2019509063A5
- Authority
- JP
- Japan
- Prior art keywords
- replication
- recombinant retrovirus
- cells
- incompetent recombinant
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241001430294 unidentified retrovirus Species 0.000 claims 35
- 229920001184 polypeptide Polymers 0.000 claims 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims 18
- 210000001744 T-lymphocyte Anatomy 0.000 claims 16
- 210000000822 natural killer cell Anatomy 0.000 claims 13
- 230000001589 lymphoproliferative effect Effects 0.000 claims 12
- 230000035897 transcription Effects 0.000 claims 8
- 238000013518 transcription Methods 0.000 claims 8
- 239000012634 fragment Substances 0.000 claims 7
- 230000010076 replication Effects 0.000 claims 7
- 230000011664 signaling Effects 0.000 claims 7
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 5
- 239000012528 membrane Substances 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 3
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 3
- 241000700605 Viruses Species 0.000 claims 3
- 230000003213 activating effect Effects 0.000 claims 3
- 230000004913 activation Effects 0.000 claims 3
- 230000031146 intracellular signal transduction Effects 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000011541 reaction mixture Substances 0.000 claims 3
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 2
- 101100118093 Drosophila melanogaster eEF1alpha2 gene Proteins 0.000 claims 2
- 101710091045 Envelope protein Proteins 0.000 claims 2
- 241000712079 Measles morbillivirus Species 0.000 claims 2
- 101710188315 Protein X Proteins 0.000 claims 2
- 102100021696 Syncytin-1 Human genes 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 102000003675 cytokine receptors Human genes 0.000 claims 2
- 108010057085 cytokine receptors Proteins 0.000 claims 2
- 230000004927 fusion Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000034217 membrane fusion Effects 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 230000004083 survival effect Effects 0.000 claims 2
- 230000026683 transduction Effects 0.000 claims 2
- 238000010361 transduction Methods 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- 241000714162 Feline endogenous virus Species 0.000 claims 1
- 102000004560 Interleukin-12 Receptors Human genes 0.000 claims 1
- 108010017515 Interleukin-12 Receptors Proteins 0.000 claims 1
- 102000004556 Interleukin-15 Receptors Human genes 0.000 claims 1
- 108010017535 Interleukin-15 Receptors Proteins 0.000 claims 1
- 102000004527 Interleukin-21 Receptors Human genes 0.000 claims 1
- 108010017411 Interleukin-21 Receptors Proteins 0.000 claims 1
- 102000010782 Interleukin-7 Receptors Human genes 0.000 claims 1
- 108010038498 Interleukin-7 Receptors Proteins 0.000 claims 1
- 241000713666 Lentivirus Species 0.000 claims 1
- 101150099493 STAT3 gene Proteins 0.000 claims 1
- 108091027967 Small hairpin RNA Proteins 0.000 claims 1
- 230000006052 T cell proliferation Effects 0.000 claims 1
- 241000711975 Vesicular stomatitis virus Species 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 230000004068 intracellular signaling Effects 0.000 claims 1
- 108091070501 miRNA Proteins 0.000 claims 1
- 239000002679 microRNA Substances 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 230000003362 replicative effect Effects 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 239000004055 small Interfering RNA Substances 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022062818A JP7474281B2 (ja) | 2016-03-19 | 2022-04-05 | リンパ球に形質導入を行うための方法及び組成物、並びにその制御された増加 |
| JP2024064510A JP2024086884A (ja) | 2016-03-19 | 2024-04-12 | リンパ球に形質導入を行うための方法及び組成物、並びにその制御された増加 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662390093P | 2016-03-19 | 2016-03-19 | |
| US62/390,093 | 2016-03-19 | ||
| US201662360041P | 2016-07-08 | 2016-07-08 | |
| US62/360,041 | 2016-07-08 | ||
| US201762467039P | 2017-03-03 | 2017-03-03 | |
| US62/467,039 | 2017-03-03 | ||
| PCT/US2017/023112 WO2017165245A2 (en) | 2016-03-19 | 2017-03-19 | Methods and compositions for transducing lymphocytes and regulated expansion thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022062818A Division JP7474281B2 (ja) | 2016-03-19 | 2022-04-05 | リンパ球に形質導入を行うための方法及び組成物、並びにその制御された増加 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019509063A JP2019509063A (ja) | 2019-04-04 |
| JP2019509063A5 true JP2019509063A5 (enExample) | 2020-04-30 |
| JP7108551B2 JP7108551B2 (ja) | 2022-07-28 |
Family
ID=58461483
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018568183A Active JP7108551B2 (ja) | 2016-03-19 | 2017-03-19 | リンパ球に形質導入を行うための方法及び組成物、並びにその制御された増加 |
| JP2022062818A Active JP7474281B2 (ja) | 2016-03-19 | 2022-04-05 | リンパ球に形質導入を行うための方法及び組成物、並びにその制御された増加 |
| JP2024064510A Pending JP2024086884A (ja) | 2016-03-19 | 2024-04-12 | リンパ球に形質導入を行うための方法及び組成物、並びにその制御された増加 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022062818A Active JP7474281B2 (ja) | 2016-03-19 | 2022-04-05 | リンパ球に形質導入を行うための方法及び組成物、並びにその制御された増加 |
| JP2024064510A Pending JP2024086884A (ja) | 2016-03-19 | 2024-04-12 | リンパ球に形質導入を行うための方法及び組成物、並びにその制御された増加 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10596274B2 (enExample) |
| EP (1) | EP3430136A2 (enExample) |
| JP (3) | JP7108551B2 (enExample) |
| KR (1) | KR102457098B1 (enExample) |
| CN (2) | CN108884460B (enExample) |
| AU (2) | AU2017236796B2 (enExample) |
| BR (1) | BR112018069075A2 (enExample) |
| CA (1) | CA3017378A1 (enExample) |
| CU (1) | CU24649B1 (enExample) |
| IL (1) | IL261713B2 (enExample) |
| MX (2) | MX2018011345A (enExample) |
| RU (1) | RU2755059C2 (enExample) |
| SG (2) | SG10202104509PA (enExample) |
| WO (1) | WO2017165245A2 (enExample) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2279253T3 (en) | 2008-04-09 | 2017-02-13 | Maxcyte Inc | Construction and application of therapeutic compositions of freshly isolated cells |
| US20150320799A1 (en) | 2012-12-20 | 2015-11-12 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| WO2016014565A2 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
| KR20180108567A (ko) | 2015-10-22 | 2018-10-04 | 주노 테라퓨틱스 게엠베하 | 형질도입을 위한 방법, 키트, 제제 및 장치 |
| WO2019055946A1 (en) * | 2017-09-18 | 2019-03-21 | F1 Oncology, Inc. | METHODS AND COMPOSITIONS FOR THE GENETIC MODIFICATION AND EXPANSION OF LYMPHOCYTES AND THE REGULATION OF THE ACTIVITY THEREOF |
| WO2020047527A2 (en) | 2018-09-02 | 2020-03-05 | F1 Bioventures, Llc | Methods and compositions for genetically modifying lymphocytes in blood or in enriched pbmcs |
| WO2021042072A1 (en) * | 2019-09-01 | 2021-03-04 | Exuma Biotech Corp. | Methods and compositions for the modification and delivery of lymphocytes |
| WO2021178701A1 (en) * | 2020-03-05 | 2021-09-10 | Exuma Biotech Corp. | Methods and compositions for the delivery of modified lymphocyte aggregates |
| US11325948B2 (en) | 2016-03-19 | 2022-05-10 | Exuma Biotech Corp. | Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL |
| US11111505B2 (en) | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| JP7282521B2 (ja) | 2016-04-08 | 2023-05-29 | パーデュー・リサーチ・ファウンデイション | Ｃａｒ ｔ細胞療法のための方法および組成物 |
| WO2017180587A2 (en) | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| CA3020923A1 (en) | 2016-04-15 | 2017-10-19 | Memorial Sloan Kettering Cancer Center | Transgenic t cell and chimeric antigen receptor t cell compositions and related methods |
| WO2017180842A1 (en) | 2016-04-15 | 2017-10-19 | Bioatla, Llc | Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof |
| EP3235908A1 (en) * | 2016-04-21 | 2017-10-25 | Ecole Normale Superieure De Lyon | Methods for selectively modulating the activity of distinct subtypes of cells |
| GB201614093D0 (en) * | 2016-08-17 | 2016-09-28 | Autolus Ltd | Vector |
| CN116970630A (zh) | 2016-08-26 | 2023-10-31 | 贝勒医学院 | 用于细胞治疗的组成型活性细胞因子受体 |
| US11332713B2 (en) | 2016-11-16 | 2022-05-17 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
| US11261428B2 (en) | 2018-03-15 | 2022-03-01 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
| CN110249046A (zh) * | 2016-12-05 | 2019-09-17 | 朱诺治疗学股份有限公司 | 用于过继细胞疗法的工程化细胞的产生 |
| US20190367876A1 (en) * | 2017-01-18 | 2019-12-05 | F1 Oncology, Inc. | Methods of transducing and expanding immune cells and uses thereof |
| EP3579870A4 (en) | 2017-02-07 | 2020-12-30 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | PHOSPHOLIPID ETHER (PLE) T CAR-LYMPHOCYTE TUMOR (CTCT) TARGETING AGENTS |
| WO2018160622A1 (en) | 2017-02-28 | 2018-09-07 | Endocyte, Inc. | Compositions and methods for car t cell therapy |
| WO2018161026A1 (en) * | 2017-03-03 | 2018-09-07 | Obsidian Therapeutics, Inc. | Il15 compositions and methods for immunotherapy |
| EP3589733A1 (en) * | 2017-03-03 | 2020-01-08 | F1 Oncology, Inc. | Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| JP2020530454A (ja) | 2017-08-07 | 2020-10-22 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 安全な細胞治療薬を生成するためのプラットフォーム |
| US10960071B2 (en) | 2017-08-07 | 2021-03-30 | The Regents Of The University Of California | Platform for generating safe cell therapeutics |
| WO2019090355A1 (en) * | 2017-11-06 | 2019-05-09 | Children's National Medical Center | Cells expressing antibodies and methods of treatment using the same |
| EP3723787A4 (en) * | 2017-12-14 | 2021-09-01 | Bluebird Bio, Inc. | DARIC INTERLEUKIN RECEPTORS |
| WO2019136288A1 (en) * | 2018-01-05 | 2019-07-11 | Maxcyte, Inc. | Chronic car treatment for cancer |
| AU2019209432A1 (en) | 2018-01-22 | 2020-08-06 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods of use for CAR T cells |
| CN111936518A (zh) | 2018-02-06 | 2020-11-13 | 西雅图儿童医院（Dba西雅图儿童研究所） | 对fl-ple标记的肿瘤表现出最佳的t细胞功能的荧光素特异性car |
| SG11202007606QA (en) * | 2018-02-17 | 2020-09-29 | Flagship Pioneering Innovations V Inc | Compositions and methods for membrane protein delivery |
| WO2019165237A1 (en) | 2018-02-23 | 2019-08-29 | Endocyte, Inc. | Sequencing method for car t cell therapy |
| BR112020020887A2 (pt) * | 2018-04-12 | 2021-04-06 | Umoja Biopharma, Inc | Vetores virais e linhagens celulares de empacotamento |
| JP7447014B2 (ja) | 2018-04-13 | 2024-03-11 | サンガモ セラピューティクス フランス | インターロイキン２３受容体に特異的なキメラ抗原受容体 |
| CN110499291B (zh) * | 2018-05-16 | 2023-11-24 | 上海赛比曼生物科技有限公司 | 无血清培养制备嵌合抗原受体t细胞的方法 |
| CN112867498A (zh) * | 2018-05-31 | 2021-05-28 | 华盛顿大学 | 使用嵌合抗原受体基因组编辑和转导t细胞以用于治疗t和b细胞恶性肿瘤的方法 |
| AU2019284911A1 (en) | 2018-06-13 | 2020-12-17 | Novartis Ag | BCMA chimeric antigen receptors and uses thereof |
| CA3105953A1 (en) | 2018-07-09 | 2020-01-16 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions and uses thereof |
| ES3042082T3 (en) * | 2018-08-31 | 2025-11-18 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| CA3111084A1 (en) * | 2018-09-02 | 2020-03-05 | Exuma Biotech, Corp | Methods and compositions for genetically modifying lymphocytes in blood or in enriched pbmcs |
| JP7257508B2 (ja) | 2018-10-08 | 2023-04-13 | アンバーストーン・バイオサイエンシーズ・インコーポレイテッド | 二重特異性および多重特異性生物学的物質の区画化されたアッセイ |
| WO2020092696A1 (en) * | 2018-10-31 | 2020-05-07 | Musc Foundation For Research Development | Ex vivo activation and expansion of t cells for adoptive cell transfer therapy |
| KR20210131991A (ko) * | 2018-11-14 | 2021-11-03 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 구획-특이적 카고 전달을 위한 조성물 및 방법 |
| US20230043255A1 (en) * | 2018-11-14 | 2023-02-09 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions for t cell delivery |
| AU2019385873A1 (en) * | 2018-11-26 | 2021-06-03 | Nkarta, Inc. | Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy |
| CN111378046B (zh) * | 2018-12-27 | 2024-03-15 | 上海细胞治疗集团有限公司 | 一种免疫效应细胞转换受体 |
| US20220136004A1 (en) * | 2019-01-11 | 2022-05-05 | Chan Zuckerberg Biohub, Inc. | Targeted In Vivo Genome Modification |
| EP3773918A4 (en) | 2019-03-05 | 2022-01-05 | Nkarta, Inc. | ANTI-CD19 CHEMERIC ANTIGEN RECEPTORS AND THEIR USE IN IMMUNOTHERAPY |
| US12440513B2 (en) | 2019-03-22 | 2025-10-14 | Albany Medical College | Methods for improving cognitive function |
| AU2020264760A1 (en) * | 2019-05-02 | 2021-11-11 | Celyad | Cells with multiplexed inhibitory RNA |
| CN114206928B (zh) * | 2019-05-08 | 2025-08-08 | 印希彼生物科学公司 | Cd33靶向免疫疗法 |
| WO2021044439A1 (en) * | 2019-09-08 | 2021-03-11 | Immunoadaptive Cell Therapy Pvt Ltd. | Inducible cytokine signals & methods for immunotherapy |
| CN114981441A (zh) * | 2019-10-16 | 2022-08-30 | 优莫佳生物制药股份有限公司 | 用于通用受体疗法的逆转录病毒载体 |
| CN112779223B (zh) * | 2019-11-08 | 2024-06-11 | 浙江煦顼技术有限公司 | 偶联嵌合抗原受体细胞及其用途 |
| CN114945382A (zh) | 2019-11-26 | 2022-08-26 | 诺华股份有限公司 | Cd19和cd22嵌合抗原受体及其用途 |
| CA3159944A1 (en) * | 2019-12-02 | 2021-06-10 | David HUSS | Therapeutic editing |
| KR20220137882A (ko) * | 2019-12-05 | 2022-10-12 | 바이셀릭스, 인크. | 보편적 세포 요법을 위한 면역 회피 기작의 조절제 |
| KR20220139319A (ko) * | 2020-01-08 | 2022-10-14 | 옵시디안 테라퓨틱스, 인크. | 조정 가능한 전사의 조절을 위한 조성물 및 방법 |
| IL295129A (en) | 2020-01-30 | 2022-09-01 | Umoja Biopharma Inc | Bispecific transduction enhancer |
| KR20230010231A (ko) * | 2020-05-11 | 2023-01-18 | 아빈투스 바이오, 인코포레이티드 | 생체내 형질도입을 위한 벡터 및 방법 |
| CN111848797B (zh) * | 2020-07-20 | 2021-02-09 | 北京鼎成肽源生物技术有限公司 | 一种靶向c-Met的单链抗体、嵌合抗原受体、重组载体、CAR-T细胞及应用 |
| US12012441B2 (en) | 2020-10-26 | 2024-06-18 | Neptune Biosciences Llc | Engineered human IL-21 cytokines and methods for using the same |
| CN115380112B (zh) * | 2020-11-02 | 2024-03-29 | 上海医药集团生物治疗技术有限公司 | 两个或多个靶点嵌合抗原受体基因工程载体及其应用 |
| CA3206009A1 (en) | 2021-01-27 | 2022-08-04 | Umoja Biopharma, Inc. | Lentivirus for generating cells expressing anti-cd19 chimeric antigen receptor |
| TW202246517A (zh) | 2021-01-28 | 2022-12-01 | 美商異基因治療有限公司 | 用於轉導免疫細胞之方法 |
| WO2022187289A1 (en) | 2021-03-01 | 2022-09-09 | Exuma Biotech Corp. | Methods and compositions for the delivery of retroviral particles |
| WO2022216906A1 (en) * | 2021-04-08 | 2022-10-13 | The Scripps Research Institute | Novel therapies with engineered effector cells |
| US11535869B2 (en) | 2021-04-08 | 2022-12-27 | Sana Biotechnology, Inc. | CD8-specific antibody constructs and compositions thereof |
| WO2022254337A1 (en) | 2021-06-01 | 2022-12-08 | Novartis Ag | Cd19 and cd22 chimeric antigen receptors and uses thereof |
| EP4377453A4 (en) * | 2021-07-26 | 2025-09-03 | Georgia Tech Res Inst | COMPOSITIONS AND METHODS FOR IN VIVO PROTEASE PROFILING BY DISPLAYING IMMUNE CELLS |
| EP4435101A4 (en) * | 2021-11-17 | 2025-11-12 | Shanghai Juncell Therapeutics Co Ltd | MEMBRANE SURFACE PROTEIN CONTAINING A GPI ANCHOR REGION |
| AR128077A1 (es) * | 2021-12-22 | 2024-03-20 | Kure Ai Inc | Método para una rápida producción de células t modificadas genéticamente |
| EP4469586A1 (en) | 2022-03-01 | 2024-12-04 | Exuma Biotech Corp. | Viral particles with membrane-bound hyaluronidase |
| CA3266371A1 (en) * | 2022-09-02 | 2024-03-07 | Myeloid Therapeutics Inc | Compositions for cell-specific expression and their uses |
| GB2639327A (en) * | 2022-09-22 | 2025-09-24 | Myeloid Therapeutics Inc | Engineered chimeric fusion protein compositions and methods of use thereof |
| CN115807020A (zh) * | 2022-09-23 | 2023-03-17 | 卡瑞济(北京)生命科技有限公司 | 白介素15受体α装甲CAR-T细胞在降低白介素15诱导的细胞毒性中的用途 |
| CN116731974B (zh) * | 2023-05-23 | 2024-11-29 | 杭州荣谷生物科技有限公司 | 病毒的制备方法和应用 |
| WO2024259051A1 (en) * | 2023-06-14 | 2024-12-19 | The Children's Medical Center Corporation | Systems and methods for modifying a polynucleotide |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| DE69233013T2 (de) | 1991-08-20 | 2004-03-04 | The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
| US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| CA2592997A1 (en) | 1992-12-03 | 1994-06-09 | Genzyme Corporation | Pseudo-adenovirus vectors |
| JP3532566B2 (ja) | 1993-06-24 | 2004-05-31 | エル． グラハム，フランク | 遺伝子治療のためのアデノウイルスベクター |
| JP3875990B2 (ja) | 1993-10-25 | 2007-01-31 | カンジ，インコーポレイテッド | 組換えアデノウイルスベクターおよび使用方法 |
| FR2713657B1 (fr) * | 1993-12-13 | 1996-03-01 | Transgene Sa | Nouveaux vecteurs pour le traitement du sida. |
| KR100445103B1 (ko) | 1994-12-09 | 2004-12-04 | 임페리얼 컬리지 이노베이션스 리미티드 | 유전자의동정 |
| AUPR074500A0 (en) * | 2000-10-13 | 2000-11-09 | Monash University | Treatment of t cell disorders |
| GB0105924D0 (en) | 2001-03-09 | 2001-04-25 | Microscience Ltd | Promoter |
| JP2008504821A (ja) * | 2004-07-01 | 2008-02-21 | バイレクシス コーポレイション | ベクター・パッケージング細胞系列 |
| WO2006055351A2 (en) * | 2004-11-08 | 2006-05-26 | Yale University | Structure-based compound design involving riboswitches |
| WO2008156987A2 (en) * | 2007-05-29 | 2008-12-24 | Yale University | Riboswitches and methods and compositions for use of and with riboswitches |
| ES2661310T3 (es) | 2009-03-09 | 2018-03-28 | Bioatla, Llc | Proteínas mirac |
| ES2911246T3 (es) | 2009-11-03 | 2022-05-18 | Hope City | Receptor del factor de crecimiento epidérmico truncado (EGFRT) para selección de células T transducidas |
| NZ723731A (en) * | 2011-04-08 | 2020-05-29 | Baylor College Medicine | Reversing the effects of the tumor microenvironment using chimeric cytokine receptors |
| GB201107768D0 (en) * | 2011-05-10 | 2011-06-22 | Univ Manchester | Riboswitches |
| EP2794662A1 (en) | 2011-12-22 | 2014-10-29 | F.Hoffmann-La Roche Ag | Full length antibody display system for eukaryotic cells and its use |
| JP6850528B2 (ja) | 2012-02-13 | 2021-03-31 | シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート | 二重特異性キメラ抗原受容体およびその治療的使用 |
| EP3868888A1 (en) * | 2012-02-29 | 2021-08-25 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Retroviral transduction using poloxamers |
| JP6420776B2 (ja) | 2013-03-05 | 2018-11-07 | ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ | 免疫療法のためのエンゲージャー細胞 |
| WO2014186169A1 (en) * | 2013-05-14 | 2014-11-20 | 3M Innovative Properties Company | Adhesive composition |
| KR102238226B1 (ko) * | 2013-05-14 | 2021-04-09 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 가공된 키메라 항원 수용체 (ｃａｒ) ｔ-세포의 인간 적용 |
| JP6588024B2 (ja) | 2013-10-28 | 2019-10-09 | ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション | 腫瘍溶解性ｈｓｖベクター |
| BR112017001821A2 (pt) | 2014-07-29 | 2017-11-21 | Cellectis | receptores de antígenos quiméricos específicos de ror1 (ntrkr1) para imunoterapia de câncer |
| EP3186284B1 (en) * | 2014-08-28 | 2022-04-06 | BioAtla, Inc. | Conditionally active chimeric antigen receptors for modified t-cells |
| GB201503500D0 (en) * | 2015-03-02 | 2015-04-15 | Ucl Business Plc | Cell |
| MA42895A (fr) * | 2015-07-15 | 2018-05-23 | Juno Therapeutics Inc | Cellules modifiées pour thérapie cellulaire adoptive |
| CN109563507B (zh) * | 2016-07-08 | 2024-03-05 | 埃克苏马生物技术公司 | 用于转导淋巴细胞及调节其活性的方法及组合物 |
| EP3589733A1 (en) * | 2017-03-03 | 2020-01-08 | F1 Oncology, Inc. | Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof |
-
2017
- 2017-03-19 SG SG10202104509PA patent/SG10202104509PA/en unknown
- 2017-03-19 BR BR112018069075-9A patent/BR112018069075A2/pt active IP Right Grant
- 2017-03-19 MX MX2018011345A patent/MX2018011345A/es unknown
- 2017-03-19 CA CA3017378A patent/CA3017378A1/en active Pending
- 2017-03-19 JP JP2018568183A patent/JP7108551B2/ja active Active
- 2017-03-19 AU AU2017236796A patent/AU2017236796B2/en active Active
- 2017-03-19 US US15/462,855 patent/US10596274B2/en active Active
- 2017-03-19 RU RU2018136607A patent/RU2755059C2/ru active
- 2017-03-19 CU CU2018000109A patent/CU24649B1/es unknown
- 2017-03-19 SG SG11201807286WA patent/SG11201807286WA/en unknown
- 2017-03-19 EP EP17714989.5A patent/EP3430136A2/en active Pending
- 2017-03-19 CN CN201780018352.1A patent/CN108884460B/zh active Active
- 2017-03-19 WO PCT/US2017/023112 patent/WO2017165245A2/en not_active Ceased
- 2017-03-19 KR KR1020187029258A patent/KR102457098B1/ko active Active
- 2017-03-19 IL IL261713A patent/IL261713B2/en unknown
- 2017-03-19 CN CN202310365875.0A patent/CN116426490A/zh active Pending
-
2018
- 2018-09-18 MX MX2025000222A patent/MX2025000222A/es unknown
-
2021
- 2021-10-14 AU AU2021250935A patent/AU2021250935A1/en active Pending
-
2022
- 2022-04-05 JP JP2022062818A patent/JP7474281B2/ja active Active
-
2024
- 2024-04-12 JP JP2024064510A patent/JP2024086884A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019509063A5 (enExample) | ||
| JP2018506983A5 (enExample) | ||
| JP2023060000A (ja) | レトロウイルスおよびレンチウイルスベクター | |
| RU2018136607A (ru) | Способы и составы для производства лимфоцитов и их регулируемого увеличения | |
| US20240093232A1 (en) | Retroviral And Lentiviral Vectors | |
| CN110506060B (zh) | 嵌合分子及其用途 | |
| JP2020074776A5 (enExample) | ||
| JP2008538174A5 (enExample) | ||
| JP2017528158A5 (enExample) | ||
| US10752668B2 (en) | Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule | |
| JP7221049B2 (ja) | レンチウイルス調製物の安定化のための緩衝液 | |
| JP2019150066A5 (enExample) | ||
| JP2019512251A5 (enExample) | ||
| CN112154204A (zh) | 基因工程化的细胞及应用 | |
| JP2009201525A5 (enExample) | ||
| JP2017537622A5 (enExample) | ||
| JP2017532966A5 (enExample) | ||
| RU2017111298A (ru) | Т-КЛЕТКИ С КОСТИМУЛИРУЮЩИМ ХИМЕРНЫМ АНТИГЕННЫМ РЕЦЕПТОРОМ, НАЦЕЛЕННЫЕ НА IL13Rα2 | |
| JPWO2020014366A5 (enExample) | ||
| Boudeffa et al. | Toward a scalable purification protocol of GaLV-TR-pseudotyped lentiviral vectors | |
| WO2004067710A2 (en) | Compositions and methods for tissue specific targeting of lentivirus vectors | |
| EP4448775A1 (en) | Modified paramyxoviridae attachment glycoproteins | |
| WO2014016383A2 (en) | Glycoproteins for pseudotyping lentivectors | |
| EP4602174A1 (en) | Viral particles targeting hematopoietic stem cells | |
| JP2019522984A5 (enExample) |